Mild atopic dermatitis lacks systemic inflammation, and shows reduced non-lesional skin abnormalities.

[1]  Hyun Je Kim,et al.  Single-cell transcriptome analysis of human skin identifies novel fibroblast subpopulation and enrichment of immune subsets in atopic dermatitis. , 2020, The Journal of allergy and clinical immunology.

[2]  J. Krueger,et al.  The proteomic skin profile of moderate-to-severe atopic dermatitis patients shows an inflammatory signature. , 2020, Journal of the American Academy of Dermatology.

[3]  L. Denis,et al.  Oral JAK/SYK-inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in atopic dermatitis. , 2019, The Journal of allergy and clinical immunology.

[4]  Ning Zhang,et al.  Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis. , 2019, The Journal of allergy and clinical immunology.

[5]  L. Denis,et al.  The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study† , 2019, The British journal of dermatology.

[6]  H. Williams,et al.  Association Between Topical Corticosteroid Use and Type 2 Diabetes in Two European Population-Based Adult Cohorts , 2019, Diabetes Care.

[7]  M. Chren,et al.  Association of Atopic Dermatitis With Sleep Quality in Children , 2019, Pediatrics.

[8]  D. Margolis,et al.  Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population. , 2019, The Journal of investigative dermatology.

[9]  L. Misery,et al.  Characteristics of Pruritus in Relation to Self-assessed Severity of Atopic Dermatitis. , 2019, Acta dermato-venereologica.

[10]  J. Silverberg,et al.  Treatment of atopic dermatitis with tralokinumab, an anti–IL‐13 mAb , 2019, The Journal of allergy and clinical immunology.

[11]  J. Krueger,et al.  Increased cardiovascular and atherosclerosis markers in blood of older atopic dermatitis patients. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[12]  J. Silverberg,et al.  Phase 2b Randomized Study of Nemolizumab in Adults with Moderate-Severe Atopic Dermatitis and Severe Pruritus. , 2019, The Journal of allergy and clinical immunology.

[13]  J. Silverberg,et al.  Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis , 2019, The Journal of allergy and clinical immunology.

[14]  E. Guttman‐Yassky,et al.  JAK Inhibitors for Atopic Dermatitis: An Update , 2018, American Journal of Clinical Dermatology.

[15]  V. Shi,et al.  Pain and Itch Are Dual Burdens in Atopic Dermatitis , 2018, Dermatitis : contact, atopic, occupational, drug.

[16]  T. Honda,et al.  Serum from Asian patients with atopic dermatitis is characterized by TH2/TH22 activation, which is highly correlated with nonlesional skin measures. , 2018, The Journal of allergy and clinical immunology.

[17]  A. Ozbay,et al.  Assessment of IL-31 levels and disease severity in children with atopic dermatitis. , 2018, Allergologia et immunopathologia.

[18]  S. Wong,et al.  Fibroblast growth factor 21 in cardio-metabolic disorders: a systematic review and meta-analysis. , 2018, Metabolism: clinical and experimental.

[19]  C. Flohr,et al.  Efficacy and safety of lebrikizumab (an anti‐IL‐13 monoclonal antibody) in adults with moderate‐to‐severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo‐controlled phase II trial (TREBLE) , 2018, Journal of the American Academy of Dermatology.

[20]  S. Nakae,et al.  IL-31 is crucial for induction of pruritus, but not inflammation, in contact hypersensitivity , 2018, Scientific Reports.

[21]  T. Mustelin,et al.  Serum biomarker profiles suggest that atopic dermatitis is a systemic disease. , 2018, The Journal of allergy and clinical immunology.

[22]  Y. Bao,et al.  Serum FGF21 Is Associated with Future Cardiovascular Events in Patients with Coronary Artery Disease , 2018, Cardiology.

[23]  J. Kim,et al.  Eosinophil-derived neurotoxin as a biomarker for disease severity and relapse in recalcitrant atopic dermatitis. , 2017, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[24]  Young-Ho Jung,et al.  An association of periostin levels with the severity and chronicity of atopic dermatitis in children , 2017, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[25]  G. Papp,et al.  Expansion of circulating follicular T helper cells associates with disease severity in childhood atopic dermatitis. , 2017, Immunology letters.

[26]  A. Dattola,et al.  The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins , 2017, Scientific Reports.

[27]  J. Krueger,et al.  Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. , 2017, The Journal of allergy and clinical immunology.

[28]  An Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease. , 2017, The Journal of investigative dermatology.

[29]  Xiaojing Wu,et al.  Association of Circulating IGFBP1 Level with the Severity of Coronary Artery Lesions in Patients with Unstable Angina , 2017, Disease markers.

[30]  S. Omar,et al.  Expression levels of transcription factor PU.1 and interleukin‐9 in atopic dermatitis and their relation to disease severity and eruption types , 2017, International journal of dermatology.

[31]  M. Suárez-Fariñas,et al.  The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but with Key Differences in Immune Regulatory Genes. , 2016, The Journal of investigative dermatology.

[32]  J. Silverberg,et al.  Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. , 2016, The New England journal of medicine.

[33]  T. Litman,et al.  Distinct molecular signatures of mild extrinsic and intrinsic atopic dermatitis , 2016, Experimental dermatology.

[34]  J. Krueger,et al.  Diverse activation and differentiation of multiple B-cell subsets in patients with atopic dermatitis but not in patients with psoriasis. , 2016, The Journal of allergy and clinical immunology.

[35]  T. Honda,et al.  The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. , 2015, The Journal of allergy and clinical immunology.

[36]  C. Flohr,et al.  Biomarkers for atopic dermatitis: a systematic review and meta-analysis , 2015, Current opinion in allergy and clinical immunology.

[37]  E. Ingelsson,et al.  Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis. , 2015, Atherosclerosis.

[38]  J. Huehn,et al.  Foxp3+ regulatory T cells are expanded in severe atopic dermatitis patients , 2015, Allergy.

[39]  X. Dou,et al.  Serum levels of thymus and activation‐regulated chemokine can be used in the clinical evaluation of atopic dermatitis , 2015, International journal of dermatology.

[40]  M. Suárez-Fariñas,et al.  Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population. , 2015, The Journal of allergy and clinical immunology.

[41]  Mayte Suárez-Fariñas,et al.  RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications. , 2015, The Journal of allergy and clinical immunology.

[42]  G. Yancopoulos,et al.  Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. , 2014, The Journal of allergy and clinical immunology.

[43]  J. Stenvang,et al.  Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability , 2014, PloS one.

[44]  J. Woodfolk,et al.  Skin Barrier Defects in Atopic Dermatitis , 2014, Current Allergy and Asthma Reports.

[45]  M. Suárez-Fariñas,et al.  Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. , 2013, The Journal of allergy and clinical immunology.

[46]  M. Suárez-Fariñas,et al.  Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. , 2012, The Journal of allergy and clinical immunology.

[47]  D. Margolis,et al.  The persistence of atopic dermatitis and filaggrin (FLG) mutations in a US longitudinal cohort. , 2012, The Journal of allergy and clinical immunology.

[48]  Arshdeep Singh,et al.  Atopic dermatitis: an overview. , 2012, American family physician.

[49]  A. Bowcock,et al.  Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. , 2011, The Journal of allergy and clinical immunology.

[50]  M. Nazarenko,et al.  Methylation profiling of DNA in the area of atherosclerotic plaque in humans , 2011, Molecular Biology.

[51]  M. Boguniewicz,et al.  Atopic dermatitis: a disease of altered skin barrier and immune dysregulation , 2011, Immunological reviews.

[52]  A. Bowcock,et al.  Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. , 2011, The Journal of allergy and clinical immunology.

[53]  J. Woodfolk,et al.  The role of regulatory T cells in atopic dermatitis. , 2011, Current problems in dermatology.

[54]  Donald Y M Leung,et al.  Recent insights into atopic dermatitis and implications for management of infectious complications. , 2010, The Journal of allergy and clinical immunology.

[55]  Lisa C. Zaba,et al.  IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. , 2009, The Journal of allergy and clinical immunology.

[56]  R. Geha,et al.  Cellular and molecular mechanisms in atopic dermatitis. , 2009, Advances in immunology.

[57]  J. Fujiwara,et al.  Serum levels of Th2 chemokines, CCL17, CCL22, and CCL27, were the important markers of severity in infantile atopic dermatitis , 2008, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[58]  Qiang Zhou,et al.  Structures and biological functions of IL-31 and IL-31 receptors. , 2008, Cytokine & growth factor reviews.

[59]  Jon M Hanifin,et al.  A Population‐Based Survey of Eczema Prevalence in the United States , 2007, Dermatitis : contact, atopic, occupational, drug.

[60]  Y. Wan,et al.  Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression , 2007, Nature.

[61]  W. Owczarek,et al.  Serum thymus and activation‐regulated chemokine, macrophage‐derived chemokine and eotaxin as markers of severity of atopic dermatitis , 2005, Allergy.

[62]  K. Hon,et al.  Serum Concentration of IL‐18 Correlates with Disease Extent in Young Children with Atopic Dermatitis , 2004, Pediatric dermatology.

[63]  M. D. de Bruin‐Weller,et al.  Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. , 2004, The Journal of allergy and clinical immunology.

[64]  C. Lam,et al.  Serum concentration of macrophage‐derived chemokine may be a useful inflammatory marker for assessing severity of atopic dermatitis in infants and young children , 2003, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[65]  Koichiro Nakamura,et al.  Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris. , 2003, The Journal of allergy and clinical immunology.

[66]  T. Makino,et al.  Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis , 2002, The British journal of dermatology.

[67]  Koichiro Nakamura,et al.  Serum macrophage‐derived chemokine (MDC) levels are closely related with the disease activity of atopic dermatitis , 2002, Clinical and experimental immunology.

[68]  Laan,et al.  Soluble E‐selectin, other markers of inflammation and disease severity in children with atopic dermatitis , 1998, The British journal of dermatology.